|
Clinical trials show Empagliflozin can prevent diabetes, cardiovascular induced deaths in patients: Experts
|
|
A Raju, Hyderabad
December 30 , 2016
|
|
|
Healthcare experts from Care and KIMS Hospitals in Hyderabad have
started clinical trials with an experimental drug which has the
potential to prevent both diabetes and cardiovascular disease in
patients.
A team of doctors, in their recent clinical study, used
Empagliflozin to treat type 2 diabetes patients having cardiovascular
disease. Interestingly in their study, it was discovered that
Empagliflozin reduced the risk of cardiovascular death by 38 per cent in
both the patients.
Dr. Bipin Sethi, an endocrinologist
affiliated to CARE Hospitals, and Dr. Dayasagar Rao, a senior consultant
cardiologist affiliated to Krishna Institute of Medical Sciences, who
did clinical studies on two patients, said that use of Empagliflozin is
one of the advanced and novel therapeutic options emerging in the recent
times. “India is home for 6th of global diabetes population and type 2
diabetes is the one of the most prevalent in India. Diabetes leads to
many other diseases and cardiovascular disease is in the forefront among
them. Though there are many ways and means to control diabetes, recent
studies have discovered that Empagliflozin therapy is most effective for
diabetes patients suffering from cardiovascular disease,” said Dr
Sethi.
Empagliflozin is the first US FDA approved medication for
reduction in risk of cardiovascular death, in adults with type 2
diabetes. The drug was tested on 7000 patients across 42 countries.
According
to healthcare experts, patients suffering from diabetes, having poor
control of blood sugar results in a long-standing progressive damage to
the blood vessels, which manifests as major cardiovascular diseases like
chest-pain, heart-attack, heart-failure, or paralysis. Cardiovascular
disease is the leading cause of death in patients with type 2 diabetes.
Highlighting
the increasing trend of cardiovascular diseases in people with type 2
diabetes, Dr. Bipin Sethi said, “The recent approval of the US FDA, for
the use of an anti-diabetic medicine Empagliflozin, for reducing the
risk of cardiovascular death in adults with type 2 diabetes and
cardiovascular disease, is a landmark progress in this dimension. For
the first time, physicians can prescribe a blood-sugar lowering
medication, which has been shown to reduce the risk of cardiovascular
death in patients with type 2 diabetes and cardiovascular disease.”
Explaining
the reason for higher incidence of cardiovascular disease in patients
with type 2 diabetes, Dr. V Dayasagar Rao said, “High blood pressure and
cholesterol in patients of diabetes, increases their risk of
cardiovascular diseases. This new treatment option approved by the US
FDA is a proven choice of treatment for diabetes management and
reduction of cardiovascular disease.”
The American Diabetes
Association recommends that in patients with long-standing type 2
diabetes and atherosclerotic cardiovascular disease, Empagliflozin or
Liraglutide should be considered as therapeutic options for reducing
cardiovascular and overall mortality.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|